NDAINTRAVENOUSSOLUTION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVDUO is a fixed-dose combination of neostigmine methylsulfate (an acetylcholinesterase inhibitor) and glycopyrrolate (an anticholinergic agent) administered intravenously. It reverses neuromuscular blockade induced by anesthetic agents during surgical procedures. The combination enhances acetylcholine availability while preventing cholinergic side effects, enabling rapid recovery from anesthesia.
Peak12.1 years to LOE
Early-stage peak lifecycle product with no direct generic competition provides stable commercial runway for brand-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREVDUO offers career opportunities in a newly approved niche product with minimal competitive pressure and strong patent protection. Positions focus on establishing market adoption in the perioperative setting across hospital and surgical center channels.
Brand ManagerField Sales Representative
Worked on PREVDUO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.